Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Radiation Oncology
•
Gastrointestinal Cancers
•
Medical Oncology
How would you treat a patient with a synchronous T1N2 non-small cell lung cancer and a T3N1 mid-rectal adenocarcinoma (MMR intact)?
What would be an optimal sequence of therapies, and what chemotherapy regimen may be best?
Related Questions
When a patient with pancreatic cancer received neoadjuvant chemo + chemo-RT, how do you manage an in-field, post operative positive margin?
How do you manage oxaliplatin-induced splenomegaly?
Which GI cancer patients do you use oral contrast in staging CT scans?
How would you approach treatment of a patient with adenocarcinoma of unknown primary only found in a left supraclavicular lymph node?
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?
Would you change treatment approach for rectal cancer with an associated intussusception?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?